Moreover, MET/HER2 amplification and RAS-mitogen-activated protein kinase can be other resistance mechanisms to osimertinib in NSCLC patients with positive T790M [27]; therefore, comprehensive genomic testing for these resistance mechanisms should be performed, and adequate treatment should be provided to achieve better survival outcomes. The gene discussed is WNK2; the disease is non-small cell lung carcinoma.